Actually, CD137-engaging mAbs, such as Urelumab or Utomilumab have already entered clinical trials for different types of tumors (e.g., melanoma or lung cancer) demonstrating their efficacy [13, 14]. The gene discussed is TNFRSF9; the disease is melanoma.